Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial
暂无分享,去创建一个
M. Stoel | C. von Birgelen | G. Linssen | J. van der Palen | F. de Man | Liefke C. van der Heijden | C. Doggen | C. Birgelen | H. Louwerenburg | Marlies M Kok | Liefke C van der Heijden | M. Z. Basalus | M. Kok | M. Löwik | K. van Houwelingen | G. K. Houwelingen | J. Palen | Hanim Sen | K. Tandjung | K. V. van Houwelingen | L. V. D. Heijden | F. H. Man
[1] J. W. Louwerenburg,et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial , 2016, The Lancet.
[2] A. Kaltoft,et al. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV. , 2016, Journal of the American College of Cardiology.
[3] P. Serruys,et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial , 2016, The Lancet.
[4] C. V. van Mieghem,et al. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). , 2015, JACC. Cardiovascular interventions.
[5] G. Stone,et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.
[6] P. Serruys,et al. Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents , 2015, Circulation. Cardiovascular interventions.
[7] S. Windecker,et al. Safety and Efficacy of Resolute Zotarolimus-Eluting Stents Compared With Everolimus-Eluting Stents: A Meta-Analysis , 2015, Circulation. Cardiovascular interventions.
[8] M. Stoel,et al. Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[9] Hyun-Jae Kang,et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness , 2014, Journal of the American College of Cardiology.
[10] H. Bøtker,et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial , 2014, The Lancet.
[11] J. Jeppesen,et al. Similar five-year outcome with paclitaxel- and sirolimus-eluting coronary stents , 2014, Scandinavian cardiovascular journal : SCJ.
[12] J. W. Louwerenburg,et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial , 2014, The Lancet.
[13] Rebecca J. Cook,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[14] A. Kastrati,et al. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. , 2013, Journal of the American College of Cardiology.
[15] H. Suryapranata,et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis , 2013, BMJ.
[16] J. W. Louwerenburg,et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. , 2013, Journal of the American College of Cardiology.
[17] C. Terkelsen,et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.
[18] M. Stoel,et al. Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[19] J. W. Louwerenburg,et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.
[20] P. Serruys,et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. , 2011, European heart journal.
[21] K. Eagle,et al. Comparison of baseline characteristics, management and outcome of patients with non-ST-segment elevation acute coronary syndrome in versus not in clinical trials. , 2010, The American journal of cardiology.
[22] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[23] P. Serruys,et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[24] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[25] R. Whitbourn,et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. , 2009, JACC. Cardiovascular interventions.
[26] A. Kastrati,et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. , 2009, Journal of the American College of Cardiology.
[27] F. Eberli,et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.
[28] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[29] M. Simoons,et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. , 2006, European heart journal.
[30] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.